STOCKHOLM, den 6 mars 2024 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) meddelar idag att 100 Emollivet-aktier, motsvarande ca 0,7 MSEK, har avyttrats till Cerbios-Pharma SA. Lipidor genomför, som tidigare meddelats, en stegvis avyttring av sitt innehav i djurbolaget Emollivet AB. Totalt har idag 100 aktier i Emollivet sålts till Cerbios-Pharma SA […]
STOCKHOLM, Sweden, 6th March 2024 – Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces that 100 Emollivet shares, corresponding to approximately SEK 0.7 million, have been divested to Cerbios-Pharma SA. As previously announced, Lipidor is carrying out a step-by-step divestment of its holding in the animal company Emollivet AB. A total of […]
STOCKHOLM, Sweden, 24th January 2024 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announces that one of the company's patents, previously out-licensed to Emollivet AB, has now been sold to the same party. The sale is aimed at strengthening Lipidor's short term cash position. Since its inception in 2019, Emollivet has held […]
STOCKHOLM, den 24 januari 2024 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) meddelar idag att ett av bolagets patent, som tidigare ut-licensierats till Emollivet AB, nu har avyttrats till samma part. Försäljningen syftar till att kortsiktigt stärka Lipidors kassa. Emollivet har sedan sin start år 2019 haft en licens på Lipidors´s IP […]
STOCKHOLM, Sweden, 21st December 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that 63 shares, corresponding to approximately 0.5 MSEK, have been sold in the associated company Emollivet, and that a loan of approximately 0.6 MSEK has been taken up from the company's largest owner, Cerbios-Pharma SA. In 2023, Lipidor […]
STOCKHOLM, den 21 december 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) meddelar idag att 63 aktier, motsvarande ca 0,5 MSEK, har avyttrats i intressebolaget Emollivet samt att ett lån om ca 0,6 MSEK tagits upp från bolagets största ägare Cerbios-Pharma SA. Under 2023 har Lipidor gjort en stegvis avyttring av innehav […]
STOCKHOLM, Sverige, 18 oktober 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) meddelar idag att en ny överenskommelse träffats med RELIFE S.r.l. avseende bolagets psoriasisprojekt. De nya villkoren avser geografisk expansion genom tillägg av Asia-Pacific regionen samt en uppdaterad tidslinje. Lipidor har sedan tidigare tecknat ett licensavtal i vilket Lipidor ger RELIFE […]
STOCKHOLM, Sweden, 18th October 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announces that a new agreement has been reached with RELIFE S.r.l. regarding the company's psoriasis project. The new terms relate to geographic expansion through the addition of the Asia-Pacific region and an updated timeline. Lipidor has previously signed a […]
STOCKHOLM, Sweden, 29th June 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces that financing of SEK 2 million is being provided through the divestment of holdings in the affiliated company Emollivet. A short-term loan of 1 million SEK has also been signed. On 22nd June, it was announced that the Swedish […]
STOCKHOLM, den 29 juni 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) meddelar att finansiering om 2 MSEK tillförs genom avyttring av innehav i intressebolaget Emollivet. Ett kortsiktigt lån om 1 MSEK har också signerats. Den 22 juni meddelades att Läkemedelsverket bekräftar den kliniska planen för en ny version av AKP02, nämligen […]